3650 Gilmore Way
Suite 200
Burnaby, BC V5G 4W8
Canada
https://www.xenon-pharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 149
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA | Pres, CEO & Director | 957.16k | N/A | 1976 |
Ms. Sherry Aulin | Chief Financial Officer | 458.64k | N/A | 1984 |
Dr. Christopher John Kenney M.D. | Chief Medical Officer | 494.83k | N/A | 1971 |
Ms. Jodi Regts M.B.A., B.A., MBA | VP of Corp. Affairs & Investor Relations | N/A | N/A | N/A |
Ms. Andrea DiFabio J.D. | Chief Legal Officer & Corp. Sec. | N/A | N/A | 1968 |
Ms. Shelley McCloskey B.A. | Exec. VP of HR | N/A | N/A | 1960 |
Dr. Robin P. Sherrington Ph.D. | Exec. VP of Strategy & Innovation | N/A | N/A | 1961 |
Dr. James R. Empfield Ph.D. | Exec. VP of Drug Discovery | N/A | N/A | 1961 |
Ms. Sheila M. Grant M.B.A., M.Sc., MBA | Exec. VP of R&D Operations | N/A | N/A | N/A |
Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D. | Chief Commercial Officer | N/A | N/A | 1979 |
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.